|
1
|
Aerts I, Lumbroso-Le Rouic L,
Gauthier-Villars M, Brisse H, Doz F and Desjardins L:
Retinoblastoma. Orphanet J Rare Dis. 1:312006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kivelä T: The epidemiological challenge of
the most frequent eye cancer: Retinoblastoma, an issue of birth and
death. Br J Ophthalmol. 93:1129–1131. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shields CL, Fulco EM, Arias JD, Alarcon C,
Pellegrini M, Rishi P, Kaliki S, Bianciotto CG and Shields JA:
Retinoblastoma frontiers with intravenous, intra-arterial,
periocular, and intra-vitreal chemotherapy. Eye (Lond). 27:253–264.
2013. View Article : Google Scholar
|
|
4
|
Abramson DH, Gerardi CM, Ellsworth RM,
McCormick B, Sussman D and Turner L: Radiation regression patterns
in treated retinoblastoma: 7 to 21 years later. J Pediatr
Ophthalmol Strabismus. 28:108–112. 1991.PubMed/NCBI
|
|
5
|
Fontanesi J, Pratt CB, Hustu HO, Coffey D,
Kun LE and Meyer D; Jude Children’s Research Hospital Experience
and Review of Literature: Use of irradiation for therapy of
retinoblastoma in children more than 1 year old: The St Jude
Children’s Research Hospital experience and review of literature.
Med Pediatr Oncol. 24:321–326. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shields CL, Say EA, Pointdujour-Lim R, Cao
C, Jabbour PM and Shields JA: Rescue intra-arterial chemotherapy
following retinoblastoma recurrence after initial intra-arterial
chemotherapy. J Fr Ophtalmol. 38:542–549. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ruiz del Río N, Abelairas Gómez JM, Alonso
García de la Rosa FJ, Peralta Calvo JM and de las Heras Martín A:
Genetic analysis results of patients with a retinoblastoma
refractory to systemic chemotherapy. Arch Soc Esp Oftalmol.
90:414–420. 2015.In Spanish. View Article : Google Scholar
|
|
8
|
Nalini V, Segu R, Deepa PR, Khetan V,
Vasudevan M and Krishnakumar S: Molecular insights on
post-chemotherapy retinoblastoma by microarray gene expression
analysis. Bioinform Biol Insights. 7:289–306. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Frankel LB and Lund AH: MicroRNA
regulation of autophagy. Carcinogenesis. 33:2018–2025. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tazawa H, Tsuchiya N, Izumiya M and
Nakagama H: Tumor-suppressive miR-34a induces senescence-like
growth arrest through modulation of the E2F pathway in human colon
cancer cells. Proc Natl Acad Sci USA. 104:15472–15477. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tarasov V, Jung P, Verdoodt B, Lodygin D,
Epanchintsev A, Menssen A, Meister G and Hermeking H: Differential
regulation of microRNAs by p53 revealed by massively parallel
sequencing: miR-34a is a p53 target that induces apoptosis and
G1-arrest. Cell Cycle. 6:1586–1593. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R,
Sun Z and Zheng X: Downregulation of CCND1 and CDK6 by miR-34a
induces cell cycle arrest. FEBS Lett. 582:1564–1568. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamakuchi M, Ferlito M and Lowenstein CJ:
miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci
USA. 105:13421–13426. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ma ZB, Kong XL, Cui G, Ren CC, Zhang YJ,
Fan SJ and Li YH: Expression and clinical significance of miRNA-34a
in colorectal cancer. Asian Pac J Cancer Prev. 15:9265–9270. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu G, Jiang C, Li D, Wang R and Wang W:
miRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in
gastric cancer. Tumour Biol. 35:9801–9806. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dalgard CL, Gonzalez M, deNiro JE and
O’Brien JM: Differential microRNA-34a expression and tumor
suppressor function in reti-noblastoma cells. Invest Ophthalmol Vis
Sci. 50:4542–4551. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gao H, Zhao H and Xiang W: Expression
level of human miR-34a correlates with glioma grade and prognosis.
J Neurooncol. 113:221–228. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li L, Yuan L, Luo J, Gao J, Guo J and Xie
X: miR-34a inhibits proliferation and migration of breast cancer
through down-regulation of Bcl-2 and SIRT1. Clin Exp Med.
13:109–117. 2013. View Article : Google Scholar
|
|
19
|
Tang Y, Tang Y and Cheng YS: miR-34a
inhibits pancreatic cancer progression through Snail1-mediated
epithelial-mesenchymal transition and the Notch signaling pathway.
Sci Rep. 7:382322017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vinall RL, Ripoll AZ, Wang S, Pan CX and
deVere White RW: miR-34a chemosensitizes bladder cancer cells to
cisplatin treatment regardless of p53-Rb pathway status. Int J
Cancer. 130:2526–2538. 2012. View Article : Google Scholar
|
|
21
|
Kang L, Mao J, Tao Y, Song B, Ma W, Lu Y,
Zhao L, Li J, Yang B and Li L: MicroRNA-34a suppresses the breast
cancer stem cell-like characteristics by downregulating Notch1
pathway. Cancer Sci. 106:700–708. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Weeraratne SD, Amani V, Neiss A, Teider N,
Scott DK, Pomeroy SL and Cho YJ: miR-34a confers chemosensitivity
through modulation of MAGE-A and p53 in medulloblastoma.
Neuro-oncol. 13:165–175. 2011. View Article : Google Scholar :
|
|
23
|
Peche LY, Scolz M, Ladelfa MF, Monte M and
Schneider C: MageA2 restrains cellular senescence by targeting the
function of PMLIV/p53 axis at the PML-NBs. Cell Death Differ.
19:926–936. 2012. View Article : Google Scholar :
|
|
24
|
Nardiello T, Jungbluth AA, Mei A,
Diliberto M, Huang X, Dabrowski A, Andrade VC, Wasserstrum R, Ely
S, Niesvizky R, et al: MAGE-A inhibits apoptosis in proliferating
myeloma cells through repression of Bax and maintenance of
survivin. Clin Cancer Res. 17:4309–4319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Krauskopf J, de Kok TM, Hebels DG,
Bergdahl IA, Johansson A, Spaeth F, Kiviranta H, Rantakokko P,
Kyrtopoulos SA and Kleinjans JC: MicroRNA profile for health risk
assessment: Environmental exposure to persistent organic pollutants
strongly affects the human blood microRNA machinery. Sci Rep.
7:92622017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jin Z, Zhan T, Tao J, Xu B, Zheng H, Cheng
Y, Yan B, Wang H, Lu G, Lin Y, et al: MicroRNA-34a induces
transdifferentiation of glioma stem cells into vascular endothelial
cells by targeting Notch pathway. Biosci Biotechnol Biochem.
81:1899–1907. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Engkvist ME, Stratford EW, Lorenz S,
Meza-Zepeda LA, Myklebost O and Munthe E: Analysis of the miR-34
family functions in breast cancer reveals annotation error of
miR-34b. Sci Rep. 7:96552017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang X and Xie X, Wang H, Xiao X, Yang L,
Tian Z, Guo X, Zhang L, Tang H and Xie X: PDL1 And LDHA act as
ceRNAs in triple negative breast cancer by regulating miR-34a. J
Exp Clin Cancer Res. 36:1292017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang X, Xie Y and Wang J: Overexpression
of microRNA-34a-5p inhibits proliferation and promotes apoptosis of
human cervical cancer cells by downregulation of Bcl-2. Oncol Res.
Aug 30–2017.Epub ahead of print. View Article : Google Scholar
|
|
30
|
Kwon H, Song K, Han C, Zhang J, Lu L, Chen
W and Wu T: Epigenetic silencing of miRNA-34a in human
cholangiocarcinoma via EZH2 and DNA methylation: Impact on
regulation of notch pathway. Am J Pathol. 187:2288–2299. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dai X, Li M and Geng F: Omega-3
polyunsaturated fatty acids eicosapentaenoic acid and
docosahexaenoic acid enhance dexamethasone sensitivity in multiple
myeloma cells by the p53/miR-34a/Bcl-2 axis. Biochemistry (Mosc).
82:826–833. 2017. View Article : Google Scholar
|
|
32
|
Ritchie W, Rasko JE and Flamant S:
MicroRNA target prediction and validation. Adv Exp Med Biol.
774:39–53. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Witkos TM, Koscianska E and Krzyzosiak WJ:
Practical aspects of microRNA target prediction. Curr Mol Med.
11:93–109. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zheng L, Zhang Y, Liu Y, Zhou M, Lu Y,
Yuan L, Zhang C, Hong M, Wang S and Li X: miR-106b induces cell
radioresistance via the PTEN/PI3K/AKT pathways and p21 in
colorectal cancer. J Transl Med. 13:2522015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lian Y, Sang M, Gu L, Liu F, Yin D, Liu S,
Huang W, Wu Y and Shan B: MAGE-A family is involved in gastric
cancer progression and indicates poor prognosis of gastric cancer
patients. Pathol Res Pract. 213:943–948. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sang M, Wu X, Fan X, Lian Y and Sang M:
MAGE-A family serves as poor prognostic markers and potential
therapeutic targets for epithelial ovarian cancer patients: A
retrospective clinical study. Gynecol Endocrinol. 33:480–484. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sang M, Gu L, Yin D, Liu F, Lian Y, Zhang
X, Liu S, Huang W, Wu Y and Shan B: MAGE-A family expression is
correlated with poor survival of patients with lung adenocarcinoma:
A retrospective clinical study based on tissue microarray. J Clin
Pathol. 70:533–540. 2017. View Article : Google Scholar
|
|
38
|
Marcar L, Maclaine NJ, Hupp TR and Meek
DW: Mage-A cancer/testis antigens inhibit p53 function by blocking
its interaction with chromatin. Cancer Res. 70:10362–10370. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zajac P, Schultz-Thater E, Tornillo L,
Sadowski C, Trella E, Mengus C, Iezzi G and Spagnoli GC: MAGE-A
antigens and cancer immunotherapy. Front Med (Lausanne).
4:182017.
|
|
40
|
Sato F, Tsuchiya S, Meltzer SJ and Shimizu
K: MicroRNAs and epigenetics. FEBS J. 278:1598–1609. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Huang Y, Shen XJ, Zou Q, Wang SP, Tang SM
and Zhang GZ: Biological functions of microRNAs: A review. J
Physiol Biochem. 67:129–139. 2011. View Article : Google Scholar
|
|
42
|
Kircelli F, Akay C and Gazitt Y: Arsenic
trioxide induces p53-dependent apoptotic signals in myeloma cells
with SiRNA-silenced p53: MAP kinase pathway is preferentially
activated in cells expressing inactivated p53. Int J Oncol.
30:993–1001. 2007.PubMed/NCBI
|
|
43
|
Riley T, Sontag E, Chen P and Levine A:
Transcriptional control of human p53-regulated genes. Nat Rev Mol
Cell Biol. 9:402–412. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Vousden KH and Prives C: Blinded by the
light: The growing complexity of p53. Cell. 137:413–431. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Monte M, Simonatto M, Peche LY, Bublik DR,
Gobessi S, Pierotti MA, Rodolfo M and Schneider C: MAGE-A tumor
antigens target p53 transactivation function through histone
deacetylase recruitment and confer resistance to chemotherapeutic
agents. Proc Natl Acad Sci USA. 103:11160–11165. 2006. View Article : Google Scholar : PubMed/NCBI
|
